Skip to main content
Top
Published in: Pain and Therapy 3/2023

Open Access 11-03-2023 | Hysteroscopy | ORIGINAL RESEARCH

Remimazolam Compared to Propofol During Hysteroscopy: A Safety and Efficacy Analysis

Authors: Shunyi Fan, Yun Zhu, Changzhong Sui, Qian Li, Wenxin Jiang, Li Zhang

Published in: Pain and Therapy | Issue 3/2023

Login to get access

Abstract

Introduction

Propofol is the main drug used to induce sedation for endoscopic procedures, and few drugs had shaken its dominant clinical use for a decade until the development of remimazolam. Remimazolam has been demonstrated to perform well in post-marketing studies on sedation for colonoscopy or other procedures requiring short periods of sedation. This study aimed to establish whether remimazolam was effective and safe for inducing sedation for hysteroscopy.

Methods

One hundred patients who were scheduled to undergo hysteroscopy were randomly assigned to receive induction with remimazolam or propofol. A dose of 0.25 mg/kg remimazolam was administered. Propofol was started at 2–2.5 mg/kg. Before remimazolam or propofol induction, 1 μg/kg fentanyl was infused. Hemodynamic parameters, vital signs, and bispectral index (BIS) values were measured and adverse events recorded to evaluate safety. We comprehensively evaluated the efficacy and safety of the two drugs by the success rate of induction, fluctuation of vital signs, depth of anesthesia, adverse reactions, recovery time, and other indicators.

Results

Information on 83 patients was successfully recorded and carefully documented. The success rate of sedation in the remimazolam group (group R) was 93%, which was lower than for the propofol group (group P) (100%), but there was no statistically significant difference between the two groups. The incidence of adverse reactions in group R (7.5%) was significantly lower than that in group P (67.4%), and the results were statistically significant (P < 0.01). The fluctuation of vital signs in group P was more severe after induction, especially in patients with cardiovascular diseases.

Conclusions

Remimazolam avoids the injection pain produced by propofol sedation, has a better pre-sedation experience, had the advantage of stable hemodynamics after injection compared to propofol, and a lower respiratory depression rate in the study patients.
Literature
1.
go back to reference Moore JF, Carugno J. Hysteroscopy. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022. Moore JF, Carugno J. Hysteroscopy. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022.
4.
go back to reference Egan TD. Is anesthesiology going soft?: trends in fragile pharmacology. Anesthesiology. 2009;111:229–30.CrossRefPubMed Egan TD. Is anesthesiology going soft?: trends in fragile pharmacology. Anesthesiology. 2009;111:229–30.CrossRefPubMed
6.
go back to reference Chen S, Wang J, Xu X, et al. The efficacy and safety of remimazolam tosylate versus propofol in patients undergoing colonoscopy: a multicentered, randomized, positive-controlled, phase III clinical trial. Am J Transl Res. 2020;12:4594–603.PubMedPubMedCentral Chen S, Wang J, Xu X, et al. The efficacy and safety of remimazolam tosylate versus propofol in patients undergoing colonoscopy: a multicentered, randomized, positive-controlled, phase III clinical trial. Am J Transl Res. 2020;12:4594–603.PubMedPubMedCentral
29.
go back to reference Dundee JW. Intravenous anaesthesia and the need for new agents. Postgrad Med J. 1985;61(Suppl 3):3–6.PubMed Dundee JW. Intravenous anaesthesia and the need for new agents. Postgrad Med J. 1985;61(Suppl 3):3–6.PubMed
Metadata
Title
Remimazolam Compared to Propofol During Hysteroscopy: A Safety and Efficacy Analysis
Authors
Shunyi Fan
Yun Zhu
Changzhong Sui
Qian Li
Wenxin Jiang
Li Zhang
Publication date
11-03-2023
Publisher
Springer Healthcare
Published in
Pain and Therapy / Issue 3/2023
Print ISSN: 2193-8237
Electronic ISSN: 2193-651X
DOI
https://doi.org/10.1007/s40122-023-00483-4

Other articles of this Issue 3/2023

Pain and Therapy 3/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine